Analysis of neoantigen-specific anti-tumor immune responses and its clinical application for personalized cancer immunotherapy

• Project/Area Number: 17H04278
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: General surgery
• Research Institution: Kanagawa Cancer Center Research Institute
• Principal Investigator: Sasada Tetsuro 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), がんワクチン・免疫センター, 部長 (70293967)
• Co-Investigator(Kenkyū-buntansha): 岸 裕幸 富山大学, 学術研究部医学系, 教授 (60186210) ; 東 公一 久留米大学, 医学部, 講師 (00368896)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000); Fiscal Year 2019: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2018: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000); Fiscal Year 2017: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
• Keywords: ネオアンチゲン / 腫瘍免疫 / 遺伝子変異 / 免疫反応 / 個別化治療 / ゼノグラフト / 抗腫瘍効果 / 細胞表面マーカー / 免疫療法

Outline of Final Research Achievements

The aim of this study was to develop the methods to efficiently identify tumor-specific T cells recognizing neoantigens in cancer patients. This study demonstrated that T cells positive for multiple T cell markers, such as immune checkpoints and co-stimulatory molecules, can recognize and respond to tumor cells, suggesting that assessment of multiple T cell markers might be useful for efficient identification of tumor-specific T cells recognizing neoantigens. These findings could establish the basic knowledge and technology to facilitate clinical application of personalized cancer immunotherapy.

Academic Significance and Societal Importance of the Research Achievements

がん免疫療法を今後さらに発展させるためには、がん特異的なＴ細胞を選択的に活性化させる特異的がん免疫療法の開発が不可欠である。ネオアンチゲンは高い免疫原性が期待できるうえに自己免疫反応を惹起する心配も少ないため、特異的がん免疫療法の格好の標的と思われる。本研究によりネオアンチゲンを認識すると思われる腫瘍反応性Ｔ細胞を効率的に同定できる手法が開発されたことから、本研究の成果は“個別化がん免疫治療”の臨床応用を加速するための知的・技術的基盤の確立に寄与するものと期待される。

Research Products

• [Journal Article] Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients (2020)
  • Author(s): Suekane Shigetaka、Yutani Shigeru、Yamada Akira、Sasada Tetsuro、Matsueda Satoko、Takamori Shinzo、Toh Uhi、Kawano Kouichiro、Yoshiyama Koichi、Sakamoto Shinjiro、Sugawara Shunichi、Komatsu Nobukazu、Yamada Teppei、Naito Masayasu、Terasaki Mizuhiko、Mine Takashi、Itoh Kyogo、Shichijo Shigeki、Noguchi Masanori
  • Journal Title: International Journal of Oncology Volume: 56 Pages: 1479-1489
  • DOI: 10.3892/ijo.2020.5019
  • Peer Reviewed / Open Access
• [Journal Article] Distribution of Regulatory T-Cells and Other Phenotypes of T-Cells in Tumors and Regional Lymph Nodes of Colorectal Cancer Patients. (2020)
  • Author(s): Kazama K, Otake J, Satoyoshi T, Shiozawa M, Sugano N, Sato S, Atsumi Y, Kano K, Murakawa M, Maezawa Y, Hashimoto I, Numata M, Oshima T, Yukawa N, Rino Y, Sasada T, Masuda M.
  • Journal Title: In Vivo. Volume: 34 Issue: 2 Pages: 849-856
  • DOI: 10.21873/invivo.11848
  • Peer Reviewed / Open Access
• [Journal Article] Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial (2020)
  • Author(s): Noguchi Masanori、Arai Gaku、Egawa Shin、Ohyama Chikara、Naito Seiji、Matsumoto Kazumasa、Uemura Hirotsugu、Nakagawa Masayuki、Nasu Yasutomo、Eto Masatoshi、Suekane Shigetaka、Sasada Tetsuro、Shichijo Shigeki、Yamada Akira、Kakuma Tatsuyuki、Itoh Kyogo
  • Journal Title: Cancer Immunology, Immunotherapy Volume: 69 Issue: 5 Pages: 847-857
  • DOI: 10.1007/s00262-020-02498-8
  • Peer Reviewed / Open Access
• [Journal Article] High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. (2020)
  • Author(s): Ohkuma R, Yada E, Ishikawa S, Komura D, Ishizaki H, Tamada K, Kubota Y, Hamada K, Ishida H, Hirasawa Y, Ariizumi H, Satoh E, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Yokobori T, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Izumizaki M, Kobayashi S, Tsunoda T, Wada S.
  • Journal Title: PLoS One Volume: 10 Issue: 1 Pages: e0226707-e0226707
  • DOI: 10.1371/journal.pone.0226707
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial (2019)
  • Author(s): Shimizu Yasuhiro、Yoshikawa Toshiaki、Kojima Takashi、Shoda Kayoko、Nosaka Kazuto、Mizuno Shoichi、Wada Satoshi、Fujimoto Yuki、Sasada Tetsuro、Kohashi Kenichi、Bando Hideaki、Endo Itaru、Nakatsura Tetsuya
  • Journal Title: Cancer Science Volume: 110 Issue: 10 Pages: 3049-3060
  • DOI: 10.1111/cas.14165
  • Peer Reviewed / Open Access
• [Journal Article] Immunological consequences following splenectomy in patients with liver cirrhosis. (2019)
  • Author(s): Hirakawa Y, Ogata T, Sasada T, Yamashita T, Itoh K, Tanaka H, Okuda K.
  • Journal Title: Exp Ther Med. Volume: 18 Pages: 848-856
  • DOI: 10.3892/etm.2019.7640
  • Peer Reviewed / Open Access
• [Journal Article] Prospects for a personalized peptide vaccine against lung cancer. (2019)
  • Author(s): Nakahara Y, Kouro T, Igarashi Y, Kawahara M, Sasada T.
  • Journal Title: Expert Rev Vaccines. Volume: 18 Issue: 7 Pages: 703-709
  • DOI: 10.1080/14760584.2019.1635461
  • Peer Reviewed
• [Journal Article] 遺伝子変異由来ネオアンチゲンを標的とした特異的免疫療法. (2019)
  • Author(s): 紅露拓，笹田哲朗
  • Journal Title: 医学のあゆみ Volume: 271 Pages: 163-168
• [Journal Article] がん免疫療法のバイオマーカーの現状および今後の展望. (2019)
  • Author(s): 松尾規和，笹田哲朗
  • Journal Title: 実験医学 増刊 「がん免疫療法の個別化を支える新・腫瘍免疫学」 Volume: 37 Pages: 180-188
• [Journal Article] Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations (2019)
  • Author(s): Iiizumi Susumu、Ohtake Junya、Murakami Naoko、Kouro Taku、Kawahara Mamoru、Isoda Fumiko、Hamana Hiroshi、Kishi Hiroyuki、Nakamura Norihiro、Sasada Tetsuro
  • Journal Title: Cancers Volume: 11 Issue: 2 Pages: 266-266
  • DOI: 10.3390/cancers11020266
  • Peer Reviewed / Open Access
• [Journal Article] Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy. (2019)
  • Author(s): Matsuo N, Azuma K, Sasada T.
  • Journal Title: Oncotarget. Volume: 10 Issue: 20 Pages: 1866-1867
  • DOI: 10.18632/oncotarget.26749
  • Peer Reviewed / Open Access
• [Journal Article] Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. (2019)
  • Author(s): Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T.
  • Journal Title: Int J Cancer. Volume: 144 Issue: 5 Pages: 1170-1179
  • DOI: 10.1002/ijc.31923
  • Peer Reviewed / Open Access
• [Journal Article] Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. (2018)
  • Author(s): Tsukagoshi M, Wada S, Hirono S, Yoshida S, Yada E, Sasada T, Shirabe K, Kuwano H, Yamaue H.
  • Journal Title: Oncotarget. Volume: 9 Issue: 59 Pages: 31448-31458
  • DOI: 10.18632/oncotarget.25837
  • Peer Reviewed / Open Access
• [Journal Article] A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. (2018)
  • Author(s): Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, Kobayashi H, Fujimaki T, Goto H, Takeshima H, Ueba T, Abe H, Tamiya T, Sonoda Y, Natsume A, Kakuma T, Sugita Y, Komatsu N, Yamada A, Sasada T, Matsueda S, Shichijo S, Itoh K, Terasaki M.
  • Journal Title: Neuro Oncol. Volume: 21 Issue: 3 Pages: 348-359
  • DOI: 10.1093/neuonc/noy200
  • Peer Reviewed / Open Access
• [Journal Article] Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. (2018)
  • Author(s): Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, Wada S, Miyagi Y, Kishida T, Sasada T.
  • Journal Title: Oncotarget. Volume: 9 Issue: 75 Pages: 34066-34078
  • DOI: 10.18632/oncotarget.26122
  • Peer Reviewed / Open Access
• [Journal Article] Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. (2018)
  • Author(s): Ono T, Azuma K, Kawahara A, Sasada T, Matsuo N, Kakuma T, Kamimura H, Maeda R, Hattori C, On K, Nagata K, Sato F, Chitose SI, Shin B, Aso T, Akiba J, Umeno H.
  • Journal Title: Head Neck. Volume: 40 Issue: 9 Pages: 2007-2019
  • DOI: 10.1002/hed.25189
  • Peer Reviewed
• [Journal Article] がんワクチン療法の将来 (2018)
  • Author(s): 飯泉 晋, 中村徳弘, 笹田哲朗.
  • Journal Title: 腫瘍内科 Volume: 22 Pages: 135-141
• [Journal Article] Immuno-Oncologyにおけるトランスレーショナルリサーチ：大腸癌手術検体の網羅的解析による各種免疫細胞の形質・機能の解析 (2018)
  • Author(s): 大竹淳矢, 風間慶祐, 塩澤学, 笹田哲朗.
  • Journal Title: 癌と化学療法 Volume: 45 Pages: 1238-1241
• [Journal Article] Use of patient-derived xenograft mouse models in cancer research and treatment. (2017)
  • Author(s): Yada E, Wada S, Yoshida S, Sasada T.
  • Journal Title: Future Sci OA. Volume: 4 Issue: 3
  • DOI: 10.4155/fsoa-2017-0136
  • Peer Reviewed / Open Access
• [Journal Article] Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. (2017)
  • Author(s): Ono T, Azuma K, Kawahara A, Sasada T, Hattori S, Sato F, Shin B, Chitose SI, Akiba J, Hirohito U.
  • Journal Title: Oncotarget. Volume: 8 Issue: 54 Pages: 92699-92714
  • DOI: 10.18632/oncotarget.21564
  • Peer Reviewed / Open Access
• [Journal Article] Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. (2017)
  • Author(s): Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M.
  • Journal Title: Cancer Sci. Volume: 108 Issue: 12 Pages: 2430-2437
  • DOI: 10.1111/cas.13404
  • Peer Reviewed / Open Access
• [Journal Article] Are peptide vaccines viable in combination with other cancer immunotherapies? (2017)
  • Author(s): Ohtake J, Sasada T.
  • Journal Title: Future Oncol. Volume: 13 Issue: 18 Pages: 1577-1580
  • DOI: 10.2217/fon-2017-0136
  • Peer Reviewed
• [Journal Article] ネオアンチゲンを標的とした免疫療法 (2017)
  • Author(s): 笹田哲朗
  • Journal Title: 医学のあゆみ がん免疫療法の躍進 Volume: 263 (1) Pages: 13-19
• [Presentation] High expression of Olfactomedin-4 correlates with chemoresistance and poor prognosis for pancreatic cancer. (2019)
  • Author(s): Ryotaro Ohkuma, Erica Yada, Yutaro Kubota, Kazuyuki Hamada, Hiroo Ishida, Yuya Hirasawa, Hirotsugu Ariizumi, Etsuko Satoh, Junji Tsurutani, Kiyoshi Yoshimura, Tetsuro Sasada, Takeshi Aoki, Masahiko Murakami, Tomoko Norose, Nobuyuki Ohike, Masafumi Takimoto, Takuya Tsunoda, Satoshi Wada.
  • Organizer: AACR Annual Meeting 2019
  • Int'l Joint Research
• [Presentation] Early changes in plasma CXCL2 and MMP2 levels predicts the response to anti-PD-1 therapy in non-small-cell lung cancer. (2019)
  • Author(s): Matsuo N, Azuma K, Murotani K, Ishii H, Tokito T, Yamada K,Shibata Y, Shimokawaji T, Nakahara Y, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T.
  • Organizer: 2019 World Conference on Lung Cancer
  • Int'l Joint Research
• [Presentation] Changes of BCR Repertoire Are Predictive Biomarker for the Efficacy of Immune Checkpoint Inhibitor in NSCLC. (2019)
  • Author(s): Azuma K, Nakahara Y, Matsuo N, Ishii H, Tokito T, Murotani K, Hoshino T, Sasada T.
  • Organizer: 2019 World Conference on Lung Cancer
  • Int'l Joint Research
• [Presentation] Immunogenicity of HLA class II-restricted neoantigens derived from driver mutations. (2019)
  • Author(s): Sasada T, Iiizumi S, Kouro T, Kawahara M, Nakamura N.
  • Organizer: Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
  • Int'l Joint Research
• [Presentation] Proteogenomics-based identifying neoantigens in refractory cancers using xenograft mice. (2019)
  • Author(s): Yuko Nakamura, Susumu Iizumi, Hiroki Ueda, Shogo Yamamoto, Kenji Tatsuno, Aya Nakayama, Kazuki Yamamoto, Taku Koro, Kyoko Hasegawa, Norihiro Nakamura, Hiroyuki Aburatani, Tetsuro Sasada, Takeshi Kawamura.
  • Organizer: 18th Human Proteome Organization World Congress
  • Int'l Joint Research
• [Presentation] Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer. (2019)
  • Author(s): Ishihara M, Kitano S, Hattori H, Miyahara Y, Kato H, Mishima H, Yamamoto N, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Ikeda H, Watanabe T, Kageyama S, Shiku H.
  • Organizer: ASCO Annual Meeting 2019
  • Int'l Joint Research
• [Presentation] A novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumor responses in synovial sarcoma patients. (2019)
  • Author(s): Hattori H, Ishihara M, Kitano S, Miyahara Y, Kato H, Mishima H, Yamamoto N, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Ikeda H, Watanabe T, Kageyama S, Shiku H.
  • Organizer: ESMO 2019 Congress
  • Int'l Joint Research
• [Presentation] Changes in plasma CXCL2 and MMP2 levels reflect response to anti-PD-1 therapy in non-small-cell lung cancer patients. (2019)
  • Author(s): Norikazu Matsuo, Koichi Azuma, Kenta Murotani, Yoshiko Naito, Hidenobu Ishii, Takaaki Tokito, Tadasuke Shimokawaji, Yoshiro Nakahara, Tetsuro Kondo, Terufumi Kato Haruhiro Saito, Kouzo Yamada, Tetsuro Sasada, Tomoaki Hoshino.
  • Organizer: 第17回日本臨床腫瘍学会学術集会
• [Presentation] Changes of BCR repertoire are predictive biomarker for the efficacy of immune checkpoint inhibitor in NSCLC. (2019)
  • Author(s): Yoshiro Nakahara, Norikazu Matsuo, Koichi Azuma, Yoshiko Naito, Hidenobu Ishii, Takaaki Tokito, Yuka Igarashi, Taku Kouro, Ryo Usui, Tadasuke Shimokawaji, Tetsuro Kondo, Terufumi Kato, Haruhiro Saito, KouzoYamada, Tomoaki Hoshino, Tetsuro Sasada.
  • Organizer: 第17回日本臨床腫瘍学会学術集会
• [Presentation] Immunogenicity of frequent driver mutations; identification of novel HLA class II-restricted neoantigens. (2019)
  • Author(s): Susumu Iiizumi, Junya Ohtake, Taku Kouro, Mamoru Kawahara, Yuka Igarashi, Norihiro Nakamura, Tetsuro Sasada.
  • Organizer: 第23回日本がん免疫学会総会
• [Presentation] B細胞受容体(BCR)のレパトア解析は非小細胞肺がんにおける免疫チェックポイント阻害剤のバイオマーカーとして有用である. (2019)
  • Author(s): 五十嵐 友香, 中原 善朗, 松尾 規和, 東 公一, 笹田 哲朗.
  • Organizer: 第23回日本がん免疫学会総会
• [Presentation] Optimization of chimeric antigen receptor construct targeting malignant mesothelioma antigen. (2019)
  • Author(s): Taku Kouro, Shoutaro Tsuji, Kohzoh Imai, Tetsuro Sasada.
  • Organizer: 第78回日本癌学会学術総会
• [Presentation] Optimization of CAR T cells recognizing malignant mesothelioma specific antigen. (2019)
  • Author(s): Taku Kouro, Kohzoh Imai, Tetsuro Sasada.
  • Organizer: 第48回日本免疫学会学術集会
• [Presentation] Enhanced lymphocyte accumulation through chemokine overexpression in tumor microenvironment. (2019)
  • Author(s): Yuka Igarashi, Junya Ohtake, Yuki Fujimoto, Tetsuro Sasada.
  • Organizer: 第48回日本免疫学会学術集会
• [Presentation] Elucidation of immunosuppressive microenvironment in colorectal cancer. (2018)
  • Author(s): Sasada T, Ohtake J, Satoyoshi T, Kazama K, Wada S, Yada E, Shiozawa M.
  • Organizer: AACR Annual Meeting 2018
  • Int'l Joint Research
• [Presentation] 乳がんに対するワクチン療法の現状と展望. (2018)
  • Author(s): 笹田哲朗.
  • Organizer: 第26回日本乳癌学会学術総会 ワークショップ「腫瘍免疫：基礎から臨床へ」
  • Invited
• [Presentation] Potential biomarkers in non-small cell lung cancer patients treated with anti-PD-1 inhibitors. (2018)
  • Author(s): Norikazu Matsuo, Koichi Azuma, Junya Ohtake, Tetsuro Sasada.
  • Organizer: 第22回日本がん免疫学会総会
• [Presentation] Inflammatory soluble factors as potential biomarkers in non-small cell lung cancer treated with anti-PD-1 inhibitors. (2018)
  • Author(s): Tetsuro Sasada, Norikazu Matsuo, Junya Ohtake, Koichi Azuma.
  • Organizer: 第77回日本癌学会学術総会
• [Presentation] Identification of therapeutic-specific mutations induced by anti-cancer drug using pancreatic cancer xenograft. (2018)
  • Author(s): Erica Yada, Tetsuro Sasada, Satoshi Wada.
  • Organizer: 第77回日本癌学会学術総会
• [Presentation] Immunogenicity and specificity of neoantigens derived from tumor-specific mutations in gastric cancer. (2018)
  • Author(s): Sasada T, Ohtake J, Iizumi S, Kouro T, Igarashi Y, Kawahara M, Yada E.
  • Organizer: The 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2018)
  • Int'l Joint Research
• [Presentation] Identification of therapeutic-specific mutations induced by gemcitabine and nab-Paclitaxel in pancreatic cancer. (2018)
  • Author(s): Erica Yada, Taku Kouro,Tetsuro Sasada, Satoshi Wada.
  • Organizer: 第47回日本免疫学会学術集会
• [Presentation] Generation of CAR T cells recognizing malignant mesothelioma specific antigen. (2018)
  • Author(s): Taku Kouro, Erica Yada, Mamoru Kawahara, Kozo Imai, Tetsuro Sasada.
  • Organizer: 第47回日本免疫学会学術集会
• [Presentation] Comprehensive analysis of T cells responsive to neoantigens derived from tumor-specific genetic mutations. (2017)
  • Author(s): Tetsuro Sasada, Junya Ohtake, Satoshi Wada, Erika Yada, Shintaro Yoshida
  • Organizer: AACR Annual Meeting 2017
  • Int'l Joint Research
• [Presentation] 大腸がんにおける免疫細胞の形質・機能の解析と免疫抑制機構の解明 (2017)
  • Author(s): 大竹淳矢、里吉哲太、和田聡、矢田英理香、三神裕美、吉田慎太郎、塩沢学、笹田哲朗
  • Organizer: 第21回日本がん免疫学会総会
• [Presentation] Elucidation of potential immune suppressive mechanisms in colorectal cancer (2017)
  • Author(s): Junya Ohtake, Tetsuta Satoyoshi, Satoshi Wada, Erika Yada, Hiromi Mikami, Shintaro Yoshida, Manabu Shiozawa, Tetsuro Sasada
  • Organizer: 第76回日本癌学会学術総会
• [Presentation] Comprehensive analysis of immunological tumor environment in colorectal cancer (2017)
  • Author(s): Junya Ohtake, Tetsuta Satoyoshi, Keisuke Kazama, Satoshi Wada, Erika Yada, Hiromi Mikami, Shintaro Yoshida, Manabu Shiozawa, Tetsuro Sasada
  • Organizer: 第46回日本免疫学会学術集会
• [Book] プレシジョン・メディシン ～ビッグデータの構築・分析から臨床応用・課題まで～. （第2編 第3章 第3節）変異遺伝子を標的とした個別化がん免疫療法の開発. (2018)
  • Author(s): 紅露拓, 笹田哲朗
  • Total Pages: 406
  • Publisher: エヌ・ティー・エス
• [Book] がん治療で起こる副作用・合併症の治療法と薬剤開発. （第4章 11節）がんワクチン (2018)
  • Author(s): 和田聡, 笹田哲朗
  • Total Pages: 508
  • Publisher: 技術情報協会
  • ISBN: 9784861047237
• [Remarks] 研究室（神奈川県立がんセンター臨床研究所 がん免疫療法研究開発学部］ホームページ
  • URL: http://kcch.kanagawa-pho.jp/kccri/organization/menekiryoho.html
• [Remarks] 研究室（神奈川県立がんセンター臨床研究所 がん免疫療法研究開発学部）ホームページ
  • URL: http://kcch.kanagawa-pho.jp/kccri/organization/menekiryoho.html
• [Remarks] 神奈川県立がんセンター臨床研究所 がん免疫療法研究開発学部
  • URL: http://kcch.kanagawa-pho.jp/kccri/organization/menekiryoho.html
• [Patent(Industrial Property Rights)] 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬 (2020)
  • Inventor(s): 笹田哲朗、大竹淳也、飯泉晋、中村徳弘、磯田扶美子、小高和彦
  • Industrial Property Rights Holder: 地方独立行政法人神奈川県立病院機構、ブライトパス・バイオ株式会社
  • Industrial Property Rights Type: 特許
  • Filing Date: 2020
  • Overseas
• [Patent(Industrial Property Rights)] がん免疫療法の予後予測のためのバイオマーカー (2018)
  • Inventor(s): 笹田哲朗、東公一、松尾規和、星野友昭
  • Industrial Property Rights Holder: 地方独立行政法 人神奈川県立病 院機構、久留米大学
  • Industrial Property Rights Type: 特許
  • Filing Date: 2018
  • Overseas